다케다, 中어센티지 '3세대 TKI' 계약금 1억弗 “옵션딜” - 바이오스펙테이터

다케다(Takeda)가 중국 어센티지파마(Ascentage Pharma)로부터 BCR-ABL 타깃 3세대 TKI(tyrosine kinase inhibitor)인 ‘올베렘바티닙(olverembatinib,

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute